News
What Are Pulmonary Function Tests and Why Are They Done? Pulmonary function tests (or PFTs) are also called lung function tests. If you have symptoms or risk factors for a lung disease such as COPD, ...
Low-dose computed tomography (LDCT) reduces radiation exposure but suffers from high noise, impacting image quality and diagnostic accuracy. Supervised learning has helped address this challenge but ...
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.
Chest CT is routinely used to characterise various pulmonary abnormalities including COPD, lung cancer, and pulmonary fibrosis. Although this practice has led to increased generation and curation of ...
This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.
Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.
Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside ...
In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...
5d
Sportschosun on MSNIdiopathic pulmonary fibrosis where lung tissue hardens like a scar...Early symptoms are similar to ...According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...
The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.
The 2014 publication of the ASCEND1 and INPULSIS2 trials and subsequent regulatory approvals of pirfenidone and nintedanib, respectively, represented a watershed moment in the treatment of patients ...
Background Smoking has been considered an important risk factor for idiopathic pulmonary fibrosis (IPF) incidence. However, there are no population-based large-scale studies demonstrating the effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results